Refractory, severe Atopic Dermatitis

Also known as: Severe, refractory Atopic dermatitis

Drug	Drug Name	Drug Description
DB14973	Abrocitinib	A kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults.
DB15091	Upadacitinib	An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies.

Drug	Drug Name	Target	Type
DB14973	Abrocitinib	Cytochrome P450 2C19	enzyme
DB14973	Abrocitinib	Cytochrome P450 2C9	enzyme
DB14973	Abrocitinib	Cytochrome P450 3A4	enzyme
DB14973	Abrocitinib	Cytochrome P450 2B6	enzyme
DB14973	Abrocitinib	Tyrosine-protein kinase JAK1	target
DB14973	Abrocitinib	P-glycoprotein 1	transporter
DB14973	Abrocitinib	Solute carrier family 22 member 1	transporter
DB14973	Abrocitinib	Tyrosine-protein kinase JAK2	target
DB14973	Abrocitinib	Tyrosine-protein kinase JAK3	target
DB14973	Abrocitinib	Non-receptor tyrosine-protein kinase TYK2	target
DB14973	Abrocitinib	Serum albumin	carrier
DB14973	Abrocitinib	Solute carrier family 22 member 8	transporter
DB15091	Upadacitinib	Tyrosine-protein kinase JAK1	target
DB15091	Upadacitinib	Cytochrome P450 3A4	enzyme
DB15091	Upadacitinib	Cytochrome P450 2D6	enzyme
DB15091	Upadacitinib	P-glycoprotein 1	transporter
DB15091	Upadacitinib	ATP-binding cassette sub-family G member 2	transporter
DB15091	Upadacitinib	Solute carrier organic anion transporter family member 1B1	transporter

Drug	Drug Name	Phase	Status	Count